Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Silver (1937)
Heart FailureThe Indian Medical Gazette, 72
J. Torrado, Chad Cain, A. Mauro, F. Romeo, Ramzi Ockaili, V. Chau, John Nestler, Teja Devarakonda, S. Ghosh, Anindita Das, Fadi Salloum (2018)
Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.Journal of the American College of Cardiology, 72 19
(2015)
Editorial Board of Chinese Journal of Cardiovascular Disease. Guidelines for the diagnosis and treatment of acute ST-segment elevation myocardial infarction
M. Simon, J. Watson, J. Baldwin, W. Wagner, H. Borovetz (2008)
Current and future considerations in the use of mechanical circulatory support devices.Annual review of biomedical engineering, 10
Y. Zhang, F. Gao, X.-Y. Zhang, Yuemei Hou, Y. Tang, S.L. Yang, S. Zhu, R.Y. Luo, Shuchi Lin (2015)
Value of human brain natriuretic peptide in treatment of acute anterior myocardial infarction evaluated via three-dimensional speckle tracking imaging.Genetics and molecular research : GMR, 14 2
Merrill Thomas, Yevgeniy Khariton, G. Fonarow, S. Arnold, L. Hill, M. Nassif, Paul Chan, J. Butler, L. Thomas, A. DeVore, Adrian Hernandez, N. Albert, J. Patterson, Fredonia Williams, J. Spertus (2020)
Association between sacubitril/valsartan initiation and real‐world health status trajectories over 18 months in heart failure with reduced ejection fractionESC Heart Failure, 8
D. Pascual-Figal, R. Wachter, M. Senni, W. Bao, A. Noè, H. Schwende, D. Butylin, M. Prescott (2020)
NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.JACC. Heart failure
J. Špinar, L. Špinarová, F. Málek, O. Ludka, J. Vítovec (2019)
(Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Czech version)Cor et Vasa
P. Kaul, J. Ezekowitz, P. Armstrong, Becky Leung, A. Savu, R. Welsh, H. Quan, M. Knudtson, F. McAlister (2013)
Incidence of heart failure and mortality after acute coronary syndromes.American heart journal, 165 3
Sean Murphy, M. Prescott, A. Maisel, J. Butler, I. Piña, G. Felker, Jonathan Ward, K. Williamson, Alexander Camacho, Ritvik Kandanelly, S. Solomon, J. Januzzi (2021)
Association Between Angiotensin Receptor–Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection FractionCirculation: Heart Failure, 14
P. Elsman, Arnoud Hof, J. Hoorntje, M. Boer, G. Borm, H. Suryapranata, J. Ottervanger, A. Gosselink, J. Dambrink, F. Zijlstra (2006)
Effect of coronary occlusion site on angiographic and clinical outcome in acute myocardial infarction patients treated with early coronary intervention.The American journal of cardiology, 97 8
SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni (2019)
Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction, 381
Stefan Chairperson, D. Norway, L. Badano, M. Borger, A. Gershlick, S. Halvorsen, J. Knuuti, M. Lenzen, K. Mahaffey, Lars Sweden, S. James (2012)
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
K. Docherty, R. Campbell, K. Brooksbank, R. Godeseth, P. Forsyth, A. McConnachie, G. Roditi, B. Stanley, P. Welsh, P. Jhund, M. Petrie, J. McMurray (2020)
Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodellingESC Heart Failure, 8
B. Ibáñez, S. James, S. Agewall, M. Antunes, C. Bucciarelli-Ducci, H. Bueno, A. Caforio, F. Crea, J. Goudevenos, S. Halvorsen, G. Hindricks, A. Kastrati, M. Lenzen, E. Prescott, M. Roffi, M. Valgimigli, C. Varenhorst, P. Vranckx, P. Widimsky (2017)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.Revista espanola de cardiologia, 70 12
D. Curley, Begoña Plaza, A. Shah, René Botnar (2018)
Molecular imaging of cardiac remodelling after myocardial infarctionBasic Research in Cardiology, 113
J. McMurray, M. Packer, Akshay Desai, J. Gong, M. Lefkowitz, A. Rizkala, J. Rouleau, V. Shi, S. Solomon, K. Swedberg, M. Zile (2014)
Angiotensin-neprilysin inhibition versus enalapril in heart failure.The New England journal of medicine, 371 11
MD JamesL.JanuzziJr, PhD MargaretF.Prescott, Mdmphmba JavedButler, Mdmhs G.MichaelFelker, MD AlanS.Maisel, KevinMcCague, PhD AlexanderCamacho, Mdmph IleanaL.Piña, MD RicardoA.Rocha, Mdmph AmilM.Shah, PharmD KristinM.Williamson, MD ScottD.Solomon, PrescottButler Januzzi, Pina Maisel, Solomon Rocha, McCague, Camacho, Camacho McCague, CamachoRocha Butler, ButlerFelker Prescott, Rocha Maisel, Solomon Williamson (2019)
Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.JAMA
T. Cahill, R. Kharbanda (2017)
Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanisms, incidence and identification of patients at riskWorld Journal of Cardiology, 9
(2015)
Guidelines for the diagnosis and treatment of acute ST-segment elevation myocardial infarction, 43
Background: Many patients present with heart failure with reduced ejection fraction (HFrEF) after acute anterior wall ST-segment elevation myocardial infarction (STEMI). The purpose of this study was to evaluate the effect of preprocedural sacubitril/valsartan on N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) and left ventricular ejection fraction (LVEF) in patients with acute anterior STEMI undergoing percutaneous coronary intervention (PCI). Methods: We enrolled patients with acute anterior wall STEMI who underwent emergency PCI at The Affiliated Hospital of Putian University from January 2019 to January 2021. Prior to PCI, patients were randomized to receive sacubitril/valsartan or valsartan. Nonculprit lesion vessels that require PCI were excluded. The primary endpoints included changes in NT-pro-BNP, LVEF, and rehospitalization for heart failure (HF) during the follow-up period. Results: Out of 109 patients who were randomized, 55 were assigned to receive sacubitril/valsartan and 54 were assigned to receive valsartan. The decrease in NT-pro-BNP concentrations and the increase in LVEF were significantly greater in the sacubitril/valsartan group than in the valsartan group. Conclusions: In patients with acute anterior wall STEMI undergoing emergency PCI, preprocedural initiation of sacubitril/valsartan therapy increased LVEF and lower NT-pro-BNP concentrations compared with valsartan therapy.
Cardiology – Karger
Published: Dec 1, 2022
Keywords: Sacubitril/valsartan; Heart failure; ST-segment elevation myocardial infarction; Percutaneous coronary intervention
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.